Zimbabwe has turned down a substantial US healthcare agreement worth $367m (£272m) over five years due to the United States' demand for confidential biological samples.
The decision was revealed following a internal memorandum dated December was disclosed, indicating that President Emmerson Mnangagwa believed the deal was "unbalanced".
An official spokesperson has since stated that the United States was seeking genetic material for scientific study and profit while was unwilling to share the benefits from future vaccines.
"We will now turn to the challenging and unfortunate task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated over $1.9bn for health programmes to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has urged further talks to secure a deal agreeable to both sides so the nation's critical HIV treatment initiative can continue.
Wider Context
Zimbabwe's decision comes after a similar case in Kenya, where a high court suspended a related deal with the US following legal challenges were raised about the security of Kenyans' health data.
After resuming the presidency recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had overseen assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing government-to-government agreements to enhance transparency and responsibility.
As per statements, Sixteen African countries have so far signed these new agreements, representing over $18.3bn in new funding.
Details of the Rejected Deal
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this partnership might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment via US-supported programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, without any corresponding promise of access to any medical innovations – such as vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"Put simply, our nation would provide the raw materials for medical research without any certainty that the end products would be available to our population should a future health crisis emerge."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its push of bilateral health agreements were undermining structures previously set up via the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing system designed to deal with future global health emergencies.
"This system is intended to ensure that when a nation contributes its samples, the resulting advantages – such as medicines and cures – are distributed fairly, not monopolised solely by those with the funds to create them."
The government's concerns regarding the US deal "are not meant as opposition to America," he added.
"We encourage further dialogue with our American counterparts on how subsequent collaboration might be designed in a manner that respects the sovereignty and dignity of both nations."
Health Experts Response
Medical experts said it acknowledged the government's concerns, but suggested that talks should continue considering much of the country's HIV programmes relied on foreign aid.
"In cases where specific concerns arise, including those relating to information security or implementation frameworks, these can frequently be addressed via detailed discussion and negotiated safeguards," the group added.
The halted deal highlights the complex challenges between receiving vital international aid and protecting local interests in an ever more data-driven world.